Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 245

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: Results of Children’s Oncology Group Trial AALL0622

Open access
Slayton, William B., Schultz, Kirk R., Kairalla, John A., Devidas, Meenakshi, Mi, Xinlei, Pulsipher, Michael A., Chang, Bill H., Mullighan, Charles, Iacobucci, Ilaria, Silverman, Lewis B., Borowitz, Michael J., Carroll, Andrew J., Heerema, Nyla A., Gastier-Foster, Julie M., Wood, Brent L., Mizrahy, Sherri L., Merchant, Thomas, Brown, Valerie I., Sieger, Lance, Siegel, Marilyn J., Raetz, Elizabeth A., Winick, Naomi J., Loh, Mignon L., Carroll, William L., Hunger, Stephen P. · 2018 · Journal of Clinical Oncology

Abstract

Purpose: Addition of imatinib to intensive chemotherapy improved survival for children and young adults with Philadelphia chromosome–positive acute lymphoblastic leukemia. Compared with imatinib, dasatinib has increased potency, CNS penetration, and activity against imatinib-resistant clones. Patients and Methods: Children’s Oncology Group (COG) trial AALL0622 (Bristol Myers Squibb trial CA180-204) tested safety and feasibility of adding dasatinib to intensive chemotherapy starting at induction day 15 in patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia age 1 to 30 years. Allogeneic hematopoietic stem-cell transplantation (HSCT) was recommended for patients at high risk based on slow response and for those with a matched family donor regardless of response after at least 11 weeks of therapy. Patients at standard risk based on rapid response received chemotherapy plus dasatinib for an additional 120 weeks. Patients with overt CNS leukemia received cranial irradiation. Results: Sixty eligible patients were enrolled. Five-year overall (OS) and event-free survival rates (± standard deviations [SD]) were 86% ± 5% and 60% ± 7% overall, 87% ± 5% and 61% ± 7% for standard-risk patients (n = 48; 19% underwent HSCT), and 89% ± 13% and 67% ± 19% for high-risk patients (n = 9; 89% underwent HSCT), respectively. Five-year cumulative incidence (± SD) of CNS relapse was 15% ± 6%. Outcomes (± SDs) were similar to those in COG AALL0031, which used the same chemotherapy with continuous imatinib: 5-year OS of 81% ± 6% versus 86% ± 5% ( P = .63) and 5-year disease-free survival of 68% ± 7% versus 60% ± 7% ( P = 0.31) for AALL0031 versus AALL0622, respectively. IKZF1 deletions, present in 56% of tested patients, were associated with significantly inferior OS and event-free survival overall and in standard-risk patients. Conclusion: Dasatinib was well tolerated with chemotherapy and provided outcomes similar to those with imatinib in COG AALL0031, where all patients received cranial irradiation. Our results support limiting HSCT to slow responders and suggest a potential role for transplantation in rapid responders with IKZF1 deletions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2017.76.7228

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 245

Metadata

Authors
Slayton, W. B., Schultz, K. R., Kairalla, J. A., Devidas, M., Mi, X., Pulsipher, M. A., Chang, B. H., Mullighan, C., Iacobucci, I., Silverman, L. B., Borowitz, M. J., Carroll, A. J., Heerema, N. A., Gastier-Foster, J. M., Wood, B. L., Mizrahy, S. L., Merchant, T., Brown, V. I., Sieger, L., Siegel, M. J., Raetz, E. A., Winick, N. J., Loh, M. L., Carroll, W. L., & Hunger, S. P.
Venue
Journal of Clinical Oncology
Published
2018-08-01
Volume
36
Issue
22
Pages
2306-2314
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2806544610
Cited by
245
References
4
FWCI
25.77
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: Results of Children’s Oncology Group Trial AALL0622. https://app.cochat.ai/papers/10.1200/jco.2017.76.7228
The paper
Slayton, W. B., Schultz, K. R., Kairalla, J. A., Devidas, M., Mi, X., Pulsipher, M. A., Chang, B. H., Mullighan, C., Iacobucci, I., Silverman, L. B., Borowitz, M. J., Carroll, A. J., Heerema, N. A., Gastier-Foster, J. M., Wood, B. L., Mizrahy, S. L., Merchant, T., Brown, V. I., Sieger, L., . . . Hunger, S. P. (2018). Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: Results of Children’s Oncology Group Trial AALL0622. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2017.76.7228

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.